Redirecting to https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400ep0031-in-ret-fusion-positive-nsclc-at-2026-asco-302786269.html